| Quarterly Financials | Mar 2015 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 |
Revenue  | 830 | 1,044 | 1,404 | 1,394 | 1,308 | 1,193 | 1,493 | 1,438 | 1,466 | 1,748 | 1,763 | 1,721 | 1,812 | 1,997 | 2,007 | 2,510 | 2,571 | 2,343 | 1,935 | 1,821 | 2,017 | 1,859 | 1,995 | 1,950 | 2,382 | 2,197 | 2,444 | 2,401 |
| Expenses | 501 | 643 | 802 | 827 | 851 | 776 | 955 | 902 | 945 | 1,030 | 1,008 | 1,010 | 1,072 | 1,109 | 1,169 | 1,396 | 1,414 | 1,406 | 1,234 | 1,299 | 1,464 | 1,274 | 1,430 | 1,366 | 1,572 | 1,496 | 1,622 | 1,576 |
| EBITDA | 328 | 401 | 602 | 567 | 457 | 418 | 538 | 536 | 521 | 717 | 755 | 711 | 740 | 888 | 837 | 1,114 | 1,157 | 937 | 701 | 522 | 553 | 585 | 565 | 584 | 810 | 701 | 822 | 825 |
| Operating Profit % | 39 % | 35 % | 39 % | 39 % | 33 % | 33 % | 34 % | 35 % | 32 % | 40 % | 42 % | 41 % | 40 % | 43 % | 41 % | 44 % | 44 % | 38 % | 33 % | 24 % | 25 % | 28 % | 25 % | 26 % | 32 % | 29 % | 31 % | 32 % |
| Depreciation | 45 | 42 | 42 | 43 | 42 | 44 | 46 | 47 | 50 | 56 | 61 | 68 | 70 | 73 | 77 | 80 | 81 | 85 | 86 | 87 | 87 | 93 | 95 | 95 | 95 | 97 | 99 | 99 |
| Interest | 1 | 1 | 0 | 3 | 0 | 0 | 4 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 1 | 0 |
| Profit Before Tax | 286 | 359 | 559 | 522 | 415 | 373 | 488 | 487 | 471 | 661 | 694 | 642 | 670 | 815 | 760 | 1,034 | 1,076 | 852 | 615 | 435 | 466 | 492 | 469 | 489 | 713 | 604 | 722 | 726 |
| Tax | 54 | 91 | 156 | 133 | 123 | 101 | 131 | 128 | 83 | 169 | 174 | 172 | 168 | 257 | 153 | 131 | 181 | 150 | 122 | 129 | 145 | 136 | 121 | 131 | 175 | 174 | 212 | 137 |
| Net Profit | 232 | 268 | 404 | 389 | 292 | 272 | 357 | 359 | 388 | 492 | 520 | 471 | 502 | 557 | 607 | 902 | 895 | 702 | 493 | 306 | 321 | 356 | 348 | 358 | 538 | 430 | 510 | 589 |
| EPS in ₹ | 17.40 | 10.08 | 15.21 | 14.67 | 11.00 | 10.26 | 13.44 | 13.53 | 14.62 | 18.54 | 19.57 | 17.73 | 18.91 | 20.99 | 22.84 | 33.99 | 33.70 | 26.44 | 18.60 | 11.56 | 12.09 | 13.41 | 13.11 | 13.50 | 20.25 | 16.20 | 19.20 | 22.20 |
Divis Laboratories
5,840.65
-70.05
(-1.19%)
Market Cap
1,56,910.50 Cr
EPS
60.27
PE Ratio
74.97
Dividend Yield
0.51 %
Industry
Healthcare52 Week High
6,285.45
52 Week Low
3,350.00
PB Ratio
11.30
Debt to Equity
0.00
Sector
Pharmaceuticals
Live Chart 
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from22 analysts
Peer Comparison Compare Peers on Screener
| Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
| 1,764.75 | 4,28,233.30 | 35.92 | 49,887.20 | 12.06 | 9,648 | 13.77 | 61.58 | |
| 5,840.65 | 1,56,910.50 | 74.97 | 8,184.00 | 0.89 | 1,600 | 64.53 | 55.23 | |
| 1,511.20 | 1,23,084.40 | 24.45 | 26,520.70 | 14.17 | 4,155 | 47.38 | 60.28 | |
| 3,245.05 | 1,10,720.70 | 58.75 | 10,785.70 | 11.59 | 1,656 | 13.54 | 61.68 | |
| 1,177.90 | 1,00,988.70 | 18.34 | 28,905.40 | 12.36 | 5,578 | 1.69 | 51.86 | |
| 2,398.05 | 97,867.10 | 48.47 | 10,615.60 | 19.57 | 1,942 | -16.38 | 56.07 | |
| 2,068.75 | 96,711.60 | 32.93 | 20,141.50 | 19.94 | 1,936 | 38.82 | 54.50 | |
| 907.35 | 92,945.80 | 20.14 | 19,831.50 | 13.82 | 3,831 | 29.92 | 48.54 | |
| 1,194.95 | 70,253.80 | 19.68 | 29,559.20 | 17.55 | 3,169 | -10.04 | 61.05 | |
| 31,101.85 | 66,026.50 | 49.49 | 6,097.20 | 10.80 | 1,201 | 16.01 | 61.04 |
Growth Rate
Revenue Growth
0.89 %
Net Income Growth
-12.28 %
Cash Flow Change
-48.72 %
ROE
-17.49 %
ROCE
-14.12 %
EBITDA Margin (Avg.)
-7.03 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Total Assets | 4,411 | 4,902 | 6,159 | 6,786 | 8,038 | 8,536 | 10,774 | 13,375 | 14,439 | 15,470 |
| Fixed Assets | 1,309 | 1,439 | 1,559 | 1,996 | 2,088 | 2,782 | 3,704 | 4,325 | 4,722 | 4,739 |
| Current Assets | 2,772 | 3,027 | 4,011 | 4,535 | 4,650 | 4,680 | 6,175 | 8,352 | 9,312 | 9,675 |
| Capital Work in Progress | 218 | 264 | 444 | 120 | 492 | 920 | 711 | 470 | 212 | 778 |
| Investments | 733 | 803 | 1,631 | 1,889 | 1,946 | 971 | 0 | 72 | 77 | 82 |
| Other Assets | 2,151 | 2,397 | 2,525 | 2,781 | 3,513 | 3,863 | 6,360 | 8,508 | 9,428 | 9,871 |
| Total Liabilities | 4,411 | 4,902 | 6,159 | 6,786 | 8,038 | 8,536 | 10,774 | 13,375 | 14,439 | 15,470 |
| Current Liabilities | 776 | 520 | 660 | 653 | 847 | 927 | 1,113 | 1,196 | 1,101 | 1,278 |
| Non Current Liabilities | 141 | 89 | 142 | 208 | 234 | 299 | 367 | 451 | 571 | 621 |
| Total Equity | 3,495 | 4,293 | 5,357 | 5,925 | 6,957 | 7,310 | 9,295 | 11,728 | 12,767 | 13,571 |
| Reserve & Surplus | 3,469 | 4,240 | 5,304 | 5,872 | 6,904 | 7,257 | 9,242 | 11,675 | 12,714 | 13,518 |
| Share Capital | 27 | 53 | 53 | 53 | 53 | 53 | 53 | 53 | 53 | 53 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | 3 | 0 | 13 | -17 | 23 | 41 | 1,987 | -816 | -1,045 | 193 |
| Investing Activities | -521 | -406 | -1,140 | -478 | -685 | -84 | 75 | -2,195 | -2,707 | -269 |
| Operating Activities | 826 | 1,038 | 1,150 | 776 | 954 | 1,216 | 1,947 | 1,912 | 2,459 | 1,261 |
| Financing Activities | -303 | -631 | 2 | -314 | -246 | -1,091 | -35 | -532 | -797 | -799 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 |
| Promoter | 51.95 % | 51.95 % | 51.95 % | 51.95 % | 51.94 % | 51.94 % | 51.94 % | 51.94 % | 51.94 % | 51.93 % | 51.93 % | 51.92 % | 51.92 % | 51.90 % | 51.89 % | 51.89 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 14.86 % | 14.68 % | 16.16 % | 17.25 % | 17.99 % |
| DIIs | 12.64 % | 12.61 % | 12.64 % | 13.40 % | 13.73 % | 13.93 % | 19.54 % | 20.67 % | 21.07 % | 21.23 % | 20.97 % | 21.88 % | 22.21 % | 21.77 % | 21.06 % | 20.54 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 9.28 % | 8.81 % | 8.87 % | 9.01 % | 9.27 % | 9.53 % | 9.20 % | 9.53 % | 9.61 % | 9.28 % | 9.02 % | 8.85 % | 8.69 % | 7.77 % | 7.41 % | 7.32 % |
| Others | 26.14 % | 26.64 % | 26.55 % | 25.64 % | 25.06 % | 24.59 % | 19.31 % | 17.86 % | 17.37 % | 17.56 % | 18.08 % | 2.48 % | 2.50 % | 2.41 % | 2.39 % | 2.26 % |
| No of Share Holders | 2,08,203 | 1,93,883 | 2,23,403 | 2,74,505 | 3,09,397 | 3,46,905 | 3,79,257 | 4,14,847 | 4,33,621 | 4,02,155 | 3,73,860 | 3,54,482 | 3,47,629 | 2,98,310 | 2,78,899 | 2,80,601 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 10 | 10 | 16 | 16 | 20 | 30 | 0.00 | 30 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.92 | 0.59 | 0.8 | 0.44 | 0.45 | 1.06 | 0.00 | 0.51 | 0.00 |
Corporate Action
Login to View
This information is available only for users of ScanX and Dhan.To proceed ahead,
LoginOpen Account
Announcements
Shareholder Meeting / Postal Ballot-Scrutinizer"s Report
Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Announcement under Regulation 30 (LODR)-Newspaper Publication
Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
Announcement under Regulation 30 (LODR)-Newspaper Publication
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Integrated Filing (Financial)
Announcement under Regulation 30 (LODR)-Change in Management
Announcement under Regulation 30 (LODR)-Change in Directorate
Board Meeting Outcome for Outcome Of Board Meeting Held On February 03 2025
Outcome Of Board Meeting Held On February 03 2025 - Financial Results For The Quarter And Nine Months Ended December 30 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Board Meeting Intimation for Intimation Of Board Meeting
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Initmation Of Commencement Of Commercial Operations At Unit III Greenfield Project At Kakinada Andhra Pradesh In Phased Manner
Closure of Trading Window
Resubmission - Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements), Regulations, 2015
Clarification /Confirmation On News Item Appearing In 'Media/Publication' Under Regulation 30 Of SEBI (LODR) Regulations, 2015
Intimation Of Action(S) Taken Or Orders Passed
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Announcement under Regulation 30 (LODR)-Newspaper Publication
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Board Meeting Outcome for Outcome Of Board Meeting - Submission Of Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2024
Submission Of Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results Of The Company For The Quarter And Half Year Ended September 30, 2024.
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Closure of Trading Window
Announcement under Regulation 30 (LODR)-Credit Rating
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Shareholder Meeting / Postal Ballot-Outcome of AGM
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Announcement under Regulation 30 (LODR)-Newspaper Publication
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Board Meeting Outcome for Outcome Of Board Meeting - Submission Of Unaudited Financial Results For The Quarter Ended June 30, 2024
Outcome Of Board Meeting - Submission Of Unaudited Financial Results For The Quarter Ended June 30, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Board Meeting Intimation for Considering And Approving The Standalone And Consolidated Unaudited Financial Results Of The Company For The Quarter Ended June 30, 2024.
US-FDA Inspection Of Company'S Unit-II Manufacturing Facility At Visakhapatnam, Andhra Pradesh
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Announcement under Regulation 30 (LODR)-Newspaper Publication
Business Responsibility and Sustainability Reporting (BRSR)
Notice Of 34Th Annual General Meeting To Be Held On Monday, August 12, 2024 At 10.00 A.M. IST Through Video Conferencing (VC) / Other Audio-Visual Means (OAVM)
Reg. 34 (1) Annual Report.
Announcement under Regulation 30 (LODR)-Newspaper Publication
Closure of Trading Window
Announcement under Regulation 30 (LODR)-Cessation
Technical Indicators
RSI(14)
Neutral 55.23
ATR(14)
Less Volatile 152.36
STOCH(9,6)
Overbought 88.72
STOCH RSI(14)
Overbought 90.21
MACD(12,26)
Bullish 38.48
ADX(14)
Weak Trend 15.76
UO(9)
Bearish 60.38
ROC(12)
Uptrend But Slowing Down 4.88
WillR(14)
Overbought -18.94
About Divis Laboratories
Divi's Laboratories Ltd is a leading pharmaceutical company specializing in the manufacture of Active Pharmaceutical Ingredients (APIs), Intermediates, and Nutraceuticals. The company operates globally with a presence in over 100 countries and has six manufacturing facilities. It offers both generic and custom synthesis services for pharmaceutical companies, supporting product development from clinical trials to market launch. Divi's Laboratories has two main subsidiaries: Divis Laboratories (USA) Inc. and Divi's Laboratories Europe AG, which focus on marketing nutraceutical products. The company has research centers in Hyderabad and at its manufacturing sites, with a focus on custom synthesis and contract research. Divi's Laboratories has expanded its operations over the years, establishing multiple manufacturing units, including special economic zones (SEZs), and has undergone various regulatory inspections and certifications. The company continues to invest in capacity expansion and infrastructure upgrades to meet growing market demands.
Listing Date
12 Mar, 2003(22 Years,
14 days)
Website
Chairperson NameRamesh B V Nimmagadda
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
